ObsEva SA (NASDAQ:OBSV) posted its quarterly earnings data on Tuesday. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.01), Briefing.com reports. The business’s quarterly revenue was up NaN% on a year-over-year basis.

ObsEva SA (NASDAQ OBSV) opened at $12.00 on Tuesday. ObsEva SA has a twelve month low of $5.00 and a twelve month high of $14.69.

OBSV has been the topic of several research reports. HC Wainwright set a $25.00 price objective on shares of ObsEva SA and gave the company a “buy” rating in a research report on Monday, October 30th. Zacks Investment Research cut shares of ObsEva SA from a “hold” rating to a “sell” rating in a research report on Saturday, August 19th. Royal Bank Of Canada initiated coverage on shares of ObsEva SA in a research report on Thursday, September 14th. They set an “outperform” rating and a $22.00 price objective on the stock. Leerink Swann restated an “outperform” rating and set a $18.00 price objective on shares of ObsEva SA in a research report on Wednesday, August 16th. Finally, Credit Suisse Group initiated coverage on shares of ObsEva SA in a research report on Monday, October 9th. They set an “outperform” rating and a $16.00 price objective on the stock. Six analysts have rated the stock with a buy rating, ObsEva SA currently has a consensus rating of “Buy” and an average price target of $18.83.

ILLEGAL ACTIVITY NOTICE: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/14/obseva-sa-obsv-posts-quarterly-earnings-results-misses-expectations-by-0-01-eps.html.

About ObsEva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.